Skip to content

Non-Invasive TMS Neuromodulation for Enduring Balance & Locomotion Restoration in Parkinson's Disease

Non-Invasive TMS Neuromodulation for Enduring Balance & Locomotion Restoration in Parkinson's Disease: A Feasibility and Pilot Study (Locom-TMS)

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02875041
Enrollment
0
Registered
2016-08-23
Start date
2016-08-31
Completion date
2018-05-02
Last updated
2019-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Keywords

rehabilitation, balance

Brief summary

This is a feasibility and exploratory pilot study of adjuvant transcranial magnetic stimulation (TMS) to physical therapy (PT) for locomotion and balance rehabilitation in Parkinson's disease patients.

Detailed description

The primary outcomes will be feasibility of pairing 10 PT training sessions for PB&G with rTMS therapy immediately following PT treatment session. Secondary outcomes will be exploratory, documenting differential clinical effects of two 'active' rTMS compared to 'sham' rTMS, to investigate ability to improve motor and functional recovery outcomes. Outcome measures will be a combination of assessments regularly conducted during PT treatment sessions validated in people with PD (these will doubly serve as our study measures) and several PD oriented outcomes.

Interventions

DEVICETranscranial Magnetic Stimulation (TMS)

Sponsors

NYU Langone Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
35 Years to 89 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of PD confirmed by a neurologist with expertise in movement disorders; * Hoehn and Yahr stage 2 to 4; * On L-Dopa and/or Dopamine Agonist daily treatment regimen; * On a stable medication regimen since at least 2 weeks prior the enrolment in the study and, in the view of the treating neurologist, unlikely to require medication adjustments in the following 3 months; * Posture, locomotion and balance deficits requiring at least 10 sessions of PT.

Exclusion criteria

* History of seizure disorder, including febrile seizures, fainting spells or syncope of unknown cause(s); * Neurological disorder other than PD including stroke (mild-to-moderate micro vascular disease is allowed), traumatic brain injury, brain tumors, hydrocephalus; * Major or unstable medical illness; * Pacemakers, neurostimulators, tattoos or metal foreign bodies in the head area (dental fillings are allowed); * Untreated depression; or Beck Depression Inventory (BDI)\>22 * Taking any of the following medications within the four weeks prior to the start of the study: imipramine, amitriptyline, doxepin, nortriptyline, maprotiline, bupropion, chlorpromazine, clozapine, foscarnet, ganciclovir, ritonavir, and theophylline; * History of moderate or severe dementia, or history of Mini Mental State Examination (MMSE) \<20 or Montreal Cognitive Assessment (MoCA) \<22; * Physical therapy treatment contraindications as determined by physiotherapist.

Design outcomes

Primary

MeasureTime frameDescription
Mini Balance Evaluation Systems Test15 Minutes(Mini-BESTest): This is a clinical balance assessment tool that asses dynamic balance through 14 items. It requires 10-15 minutes to be administered. Physical therapists at Rusk use this scale during their normal evaluative sessions.
Five times sit to stand (5XSST)5 MinutesThis is a measure of functional lower limb muscle strength and may be useful in quantifying functional change of transitional movements. Physical therapists use this scale during their normal evaluative sessions. We will use those data collected for our outcome purposes. It requires \< 5 minutes to be administered. It is highly recommended and validated in PD by Parkinson's task force PD EDGE.
Timed up and go (TUG):3 MinutesAssess walking speed in meters per second over a short duration. Time is measured as subject walks a set distance. Physical therapists use this scale during their normal evaluative sessions.
Unified Parkinson's Disease Rating Scale (UPDRS)15 MinutesThe UPDRS is a Parkinson's rating scale which includes evaluations of mentation, behavior, mood, and activities of daily life as well as a clinician scored evaluation to assess motor symptoms of Parkinson's disease.
Clinical Global Impression Scale-Severity and Improvement (CGI-S and CGI-I15 MinutesCGI was designed to provide a brief stand-alone assessment of the clinician's view of the patient's global functioning prior to and after initiating a study medication. Its use has expanded to assess prior to and after any intervention. It takes less than a minute to administer by an experienced rater and it is a great tool to track clinical progress across time.
Parkinson's disease questionnaire-39 (PDQ-39)20 MinutesSelf-report questionnaire that assess PD-specific health related quality over the last month. It assessed how often patients experience difficulties across 8 quality of life dimensions and asses impact of PD on specific dimensions of functioning and well-being. It has become the most frequently used disease-specific measure of health status. It takes 10-20 minutes to be administered.
New Freezing of Gait Questionnaire (NFOG-Q)20 MinutesThis questionnaire will ask questions about symptoms of gait freezing (not being able to move). The NFOG-Q is a reliable tool to detect and evaluate the impact and severity of FOG in PD.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026